肝脏影像报告和数据系统2018版LR-5分类诊断肝细胞癌:一项更新的Meta分析
该Meta分析纳入48项研究、9031例患者、10547个观察灶和7216个肝细胞癌,评估LI-RADS v2018 LR-5诊断肝细胞癌的效能。汇总每观察灶敏感度66%(95%CI 61-70%)、特异度91%(95%CI 89-93%);细胞外对比剂MRI敏感度77%高于CT的66%(p=0.023)和钆塞酸二钠MRI的65%(p=0.001),各模态特异度无显著差异。
要点
- LR-5诊断HCC汇总敏感度66%、特异度91%,特异度不受模态或对比剂类型影响。
- 细胞外对比剂MRI敏感度77%,高于CT的66%(p=0.023)和钆塞酸二钠MRI的65%(p=0.001)。
- 各模态特异度88-93%,差异无统计学意义(p=0.084-0.803)。
核心结论
- LI-RADS v2018 LR-5对HCC诊断具有高特异度,且不受影像模态或MRI对比剂类型影响;细胞外对比剂MRI敏感度高于CT或钆塞酸二钠MRI。
研究设计与样本
- 更新版Meta分析,检索MEDLINE和Embase数据库,纳入48项报告LI-RADS v2018 LR-5诊断HCC效能的研究,共9031例患者、10547个观察灶、7216个HCC,采用双变量随机效应模型计算汇总每观察灶敏感度和特异度并按影像模态及MRI对比剂类型行亚组分析。
诊断标准与关键数值
- LR-5诊断HCC的汇总每观察灶敏感度为66%(95%CI 61-70%)、特异度为91%(95%CI 89-93%)。
临床应用与阅片要点
- 亚组分析显示细胞外对比剂MRI汇总敏感度77%(95%CI 70-82%),高于CT的66%(95%CI 58-73%;p=0.023)和钆塞酸二钠MRI的65%(95%CI 60-70%;p=0.001);细胞外对比剂MRI与钆贝葡胺MRI的73%(95%CI 61-82%)无显著差异(p=0.495)。
局限性
- 作者在临床相关性声明中指出,改进标准以提高LR-5诊断HCC的敏感度并维持高特异度可能是未来重要方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We performed an updated meta-analysis to determine the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS, LR) 5 category for hepatocellular carcinoma (HCC) using LI-RADS version 2018 (v2018), and to evaluate differences by imaging modalities and type of MRI contrast material.
METHODS: The MEDLINE and Embase databases were searched for studies reporting the performance of LR-5 using v2018 for diagnosing HCC. A bivariate random-effects model was used to calculate the pooled per-observation sensitivity and specificity. Subgroup analysis was performed based on imaging modalities and type of MRI contrast material.
RESULTS: Forty-eight studies qualified for the meta-analysis, comprising 9031 patients, 10,547 observations, and 7216 HCCs. The pooled per-observation sensitivity and specificity of LR-5 for diagnosing HCC were 66% (95% CI, 61-70%) and 91% (95% CI, 89-93%), respectively. In the subgroup analysis, MRI with extracellular agent (ECA-MRI) showed significantly higher pooled sensitivity (77% [95% CI, 70-82%]) than CT (66% [95% CI, 58-73%]; p = 0.023) or MRI with gadoxetate (Gx-MRI) (65% [95% CI, 60-70%]; p = 0.001), but there was no significant difference between ECA-MRI and MRI with gadobenate (gadobenate-MRI) (73% [95% CI, 61-82%]; p = 0.495). Pooled specificities were 88% (95% CI, 80-93%) for CT, 92% (95% CI, 86-95%) for ECA-MRI, 93% (95% CI, 91-95%) for Gx-MRI, and 91% (95% CI, 84-95%) for gadobenate-MRI without significant differences (p = 0.084-0.803).
CONCLUSIONS: LI-RADS v2018 LR-5 provides high specificity for HCC diagnosis regardless of modality or contrast material, while ECA-MRI showed higher sensitivity than CT or Gx-MRI.
CLINICAL RELEVANCE STATEMENT: Refinement of the criteria for improving sensitivity while maintaining high specificity of LR-5 for HCC diagnosis may be an essential future direction.
KEY POINTS: • The pooled per-observation sensitivity and specificity of LR-5 for diagnosing HCC using LI-RADSv2018 were 66% and 91%, respectively. • ECA-MRI showed higher sensitivity than CT (77% vs 66%, p = 0.023) or Gx-MRI (77% vs 65%, p = 0.001). • LI-RADS v2018 LR-5 provides high specificity (88-93%) for HCC diagnosis regardless of modality or contrast material type.
引用
- Lee S, Kim YY, Shin J, et al. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis. Eur Radiol. 2023. PMID: 37656177. doi:10.1007/s00330-023-10134-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。